Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Clears Third Wave Invader Pharmacogenetic Test

This article was originally published in The Gray Sheet

Executive Summary

Oncologists will be able to use Third Wave Technologies' Invader UGT1A1 molecular assay to select appropriate doses of Pfizer's chemotherapy drug Camptosar (irinotecan)for colorectal cancer, following 510(k) clearance Aug. 22
Advertisement

Related Content

Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action
Warfarin Labeling Change: Genetic Test Firms Anxiously Await FDA Action
Lower Drug Dose Spells Trouble For Pharmacogenetic Test
Unfinished Business: Demonstrating Value In Pharmacogenomic Testing
Third Wave, Now An IVD Company, Is Banking On Personalized Medicine
New Genetic Test Guidance Narrows Focus To Mutation Marker Assays
Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock
Genzyme/Third Wave
Advertisement
UsernamePublicRestriction

Register

MT022577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel